Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000731418 | SCV000859234 | uncertain significance | not provided | 2018-01-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001484196 | SCV001688608 | likely benign | Kabuki syndrome | 2024-12-26 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000731418 | SCV001874803 | likely benign | not provided | 2021-02-15 | criteria provided, single submitter | clinical testing | |
ITMI | RCV000121374 | SCV000085556 | not provided | not specified | 2013-09-19 | no assertion provided | reference population | |
Prevention |
RCV004530006 | SCV004709367 | uncertain significance | KMT2D-related disorder | 2024-03-01 | no assertion criteria provided | clinical testing | The KMT2D c.2222C>T variant is predicted to result in the amino acid substitution p.Pro741Leu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.026% of alleles in individuals of African descent in gnomAD. Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |